How much did Nxera Pharma Co achieve in EBIT for the current year?
In the current year, Nxera Pharma Co has achieved an EBIT of 0 JPY.
In 2024, Nxera Pharma Co's EBIT was 0 JPY, a 0% increase from the -10.46 B JPY EBIT recorded in the previous year.
YEAR | EBIT (undefined JPY) |
---|---|
2026e | - |
2025e | - |
2024e | - |
2023 | -10.46 |
2022 | 2.81 |
2021 | 6.91 |
2020 | 0.85 |
2019 | 0.96 |
2018 | -5.54 |
2017 | -2.46 |
2016 | 12.13 |
2015 | 0.93 |
2014 | 1.03 |
2013 | 0.68 |
2012 | -0.95 |
2011 | -1.96 |
2010 | -1.88 |
2009 | -1.86 |
2008 | -3.67 |
2007 | -6.27 |
2006 | -6.65 |
2005 | -4.41 |
2004 | -1.75 |
3 years
5 years
10 years
25 Years
Max
Gain insights into Nxera Pharma Co, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Nxera Pharma Co from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Nxera Pharma Co’s net earnings, an ultimate measure of its financial health and profitability.
Observe the yearly bars to understand the annual performance and growth of Nxera Pharma Co. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
The expected values for the forthcoming years offer investors a glimpse into Nxera Pharma Co’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Leveraging the comparison between Revenue and EBIT helps in assessing Nxera Pharma Co’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Nxera Pharma Co’s growth potential.
Date | Nxera Pharma Co Revenue | Nxera Pharma Co EBIT | Nxera Pharma Co Net Income |
---|---|---|---|
2026e | 45.62 B undefined | 0 undefined | 4.55 B undefined |
2025e | 41.06 B undefined | 0 undefined | 5.2 B undefined |
2024e | 36.6 B undefined | 0 undefined | 2.49 B undefined |
2023 | 12.77 B undefined | -10.46 B undefined | -7.19 B undefined |
2022 | 15.57 B undefined | 2.81 B undefined | 382 M undefined |
2021 | 17.71 B undefined | 6.91 B undefined | 1.02 B undefined |
2020 | 8.84 B undefined | 854 M undefined | 1.48 B undefined |
2019 | 9.73 B undefined | 960 M undefined | 1.43 B undefined |
2018 | 2.87 B undefined | -5.54 B undefined | -5.98 B undefined |
2017 | 6.96 B undefined | -2.46 B undefined | -2.65 B undefined |
2016 | 18.9 B undefined | 12.13 B undefined | 9.31 B undefined |
2015 | 8.15 B undefined | 930 M undefined | -1.43 B undefined |
2014 | 3.67 B undefined | 1.03 B undefined | 516 M undefined |
2013 | 2.07 B undefined | 682 M undefined | 1.53 B undefined |
2012 | 1.96 B undefined | -953 M undefined | -647 M undefined |
2011 | 862 M undefined | -1.96 B undefined | -1.95 B undefined |
2010 | 717 M undefined | -1.88 B undefined | -1.87 B undefined |
2009 | 920 M undefined | -1.86 B undefined | -1.77 B undefined |
2008 | 153 M undefined | -3.67 B undefined | -3.94 B undefined |
2007 | 709 M undefined | -6.27 B undefined | -6.5 B undefined |
2006 | 740 M undefined | -6.65 B undefined | -6.24 B undefined |
2005 | 416 M undefined | -4.41 B undefined | -4.18 B undefined |
2004 | 244 M undefined | -1.75 B undefined | -1.82 B undefined |
Revenue | EBIT | Net Income | |
---|---|---|---|
2004 | 244 M JPY | -1.75 B JPY | -1.82 B JPY |
2005 | 416 M JPY | -4.41 B JPY | -4.18 B JPY |
2006 | 740 M JPY | -6.65 B JPY | -6.24 B JPY |
2007 | 709 M JPY | -6.27 B JPY | -6.5 B JPY |
2008 | 153 M JPY | -3.67 B JPY | -3.94 B JPY |
2009 | 920 M JPY | -1.86 B JPY | -1.77 B JPY |
2010 | 717 M JPY | -1.88 B JPY | -1.87 B JPY |
2011 | 862 M JPY | -1.96 B JPY | -1.95 B JPY |
2012 | 1.96 B JPY | -953 M JPY | -647 M JPY |
2013 | 2.07 B JPY | 682 M JPY | 1.53 B JPY |
2014 | 3.67 B JPY | 1.03 B JPY | 516 M JPY |
2015 | 8.15 B JPY | 930 M JPY | -1.43 B JPY |
2016 | 18.9 B JPY | 12.13 B JPY | 9.31 B JPY |
2017 | 6.96 B JPY | -2.46 B JPY | -2.65 B JPY |
2018 | 2.87 B JPY | -5.54 B JPY | -5.98 B JPY |
2019 | 9.73 B JPY | 960 M JPY | 1.43 B JPY |
2020 | 8.84 B JPY | 854 M JPY | 1.48 B JPY |
2021 | 17.71 B JPY | 6.91 B JPY | 1.02 B JPY |
2022 | 15.57 B JPY | 2.81 B JPY | 382 M JPY |
2023 | 12.77 B JPY | -10.46 B JPY | -7.19 B JPY |
2024e | 36.6 B JPY | 0 JPY | 2.49 B JPY |
2025e | 41.06 B JPY | 0 JPY | 5.2 B JPY |
2026e | 45.62 B JPY | 0 JPY | 4.55 B JPY |
3 years
5 years
10 years
25 Years
Max
The gross margin, expressed as a percentage, delineates the gross profit made from the Nxera Pharma Co's sales revenue. A higher gross margin percentage indicates that the Nxera Pharma Co retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT margin represents the Nxera Pharma Co's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
The revenue margin demonstrates the Nxera Pharma Co's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Nxera Pharma Co's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Nxera Pharma Co. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Nxera Pharma Co's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Nxera Pharma Co Gross margin | Nxera Pharma Co Profit margin | Nxera Pharma Co EBIT margin | Nxera Pharma Co Profit margin |
---|---|---|---|
2026e | 75.7 % | 0 % | 9.97 % |
2025e | 75.7 % | 0 % | 12.66 % |
2024e | 75.7 % | 0 % | 6.79 % |
2023 | 75.7 % | -81.94 % | -56.34 % |
2022 | 94.05 % | 18.06 % | 2.45 % |
2021 | 94.73 % | 39.01 % | 5.74 % |
2020 | 91.39 % | 9.66 % | 16.73 % |
2019 | 91.25 % | 9.87 % | 14.72 % |
2018 | 88.34 % | -193 % | -208.11 % |
2017 | 75.7 % | -35.4 % | -38.16 % |
2016 | 75.7 % | 64.16 % | 49.26 % |
2015 | 99.95 % | 11.41 % | -17.57 % |
2014 | 75.7 % | 28.11 % | 14.06 % |
2013 | 87.83 % | 32.95 % | 73.72 % |
2012 | 83.36 % | -48.65 % | -33.03 % |
2011 | 70.53 % | -227.61 % | -226.68 % |
2010 | 92.89 % | -261.65 % | -261.09 % |
2009 | 86.09 % | -201.63 % | -192.28 % |
2008 | 20.26 % | -2,397.39 % | -2,574.51 % |
2007 | 82.79 % | -884.34 % | -917.35 % |
2006 | 33.65 % | -898.78 % | -843.24 % |
2005 | 12.26 % | -1,059.38 % | -1,003.85 % |
2004 | 94.67 % | -718.44 % | -745.9 % |
Gross margin | EBIT margin | Profit margin | |
---|---|---|---|
2004 | 94.67 % | -718.44 % | -745.9 % |
2005 | 12.26 % | -1,059.38 % | -1,003.85 % |
2006 | 33.65 % | -898.78 % | -843.24 % |
2007 | 82.79 % | -884.34 % | -917.35 % |
2008 | 20.26 % | -2,397.39 % | -2,574.51 % |
2009 | 86.09 % | -201.63 % | -192.28 % |
2010 | 92.89 % | -261.65 % | -261.09 % |
2011 | 70.53 % | -227.61 % | -226.68 % |
2012 | 83.36 % | -48.65 % | -33.03 % |
2013 | 87.83 % | 32.95 % | 73.72 % |
2014 | 75.7 % | 28.11 % | 14.06 % |
2015 | 99.95 % | 11.41 % | -17.57 % |
2016 | 75.7 % | 64.16 % | 49.26 % |
2017 | 75.7 % | -35.4 % | -38.16 % |
2018 | 88.34 % | -193 % | -208.11 % |
2019 | 91.25 % | 9.87 % | 14.72 % |
2020 | 91.39 % | 9.66 % | 16.73 % |
2021 | 94.73 % | 39.01 % | 5.74 % |
2022 | 94.05 % | 18.06 % | 2.45 % |
2023 | 75.7 % | -81.94 % | -56.34 % |
2024e | 75.7 % | 0 % | 6.79 % |
2025e | 75.7 % | 0 % | 12.66 % |
2026e | 75.7 % | 0 % | 9.97 % |
Nxera Pharma Co's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.
A yearly comparison of Nxera Pharma Co's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.
Nxera Pharma Co's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.
Fluctuations in Nxera Pharma Co’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.
In the current year, Nxera Pharma Co has achieved an EBIT of 0 JPY.
EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Nxera Pharma Co.
The EBIT of Nxera Pharma Co has increased by 0% decreased compared to the previous year.
EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.
Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.
EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.
Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.
The EBIT of Nxera Pharma Co is listed in the income statement.
EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.
The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.
Over the past 12 months, Nxera Pharma Co paid a dividend of 2.5 JPY . This corresponds to a dividend yield of about 0.18 %. For the coming 12 months, Nxera Pharma Co is expected to pay a dividend of 0 JPY.
The current dividend yield of Nxera Pharma Co is 0.18 %.
Nxera Pharma Co pays a quarterly dividend. This is distributed in the months of .
Nxera Pharma Co paid dividends every year for the past 0 years.
For the upcoming 12 months, dividends amounting to 0 JPY are expected. This corresponds to a dividend yield of 0 %.
Nxera Pharma Co is assigned to the 'Health' sector.
To receive the latest dividend of Nxera Pharma Co from 6/24/2015 amounting to 10 JPY, you needed to have the stock in your portfolio before the ex-date on 3/27/2015.
The last dividend was paid out on 6/24/2015.
In the year 2023, Nxera Pharma Co distributed 0 JPY as dividends.
The dividends of Nxera Pharma Co are distributed in JPY.
Our stock analysis for Nxera Pharma Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Nxera Pharma Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.